There are 2949 resources available
1495P - FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Final results from the phase II RAMIRIS Study of the AIO
Presenter: Peter Thuss-Patience
Session: E-Poster Display
Resources:
Abstract
1496TiP - Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma
Presenter: Florian Lordick
Session: E-Poster Display
Resources:
Abstract
1497TiP - REACTION – a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced esophagogastric cancer
Presenter: Vincent Lam
Session: E-Poster Display
Resources:
Abstract
1498TiP - A multi-center, randomized, open-label, phase III study of sintilimab + ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-106)
Presenter: Ruihua Xu
Session: E-Poster Display
Resources:
Abstract
1499TiP - FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – The phase II/III RAMIRIS study
Presenter: Salah-Eddin Al-Batran
Session: E-Poster Display
Resources:
Abstract
1500TiP - A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)
Presenter: Yelena Janjigian
Session: E-Poster Display
Resources:
Abstract
1501TiP - Changes in the tumour immune microenvironment in oesophageal squamous cell carcinoma patients receiving different neoadjuvant therapies
Presenter: Wei Li Wang
Session: E-Poster Display
Resources:
Abstract
1502TiP - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO
Presenter: Sylvie Lorenzen
Session: E-Poster Display
Resources:
Abstract
1503TiP - A prospective study of apatinib in combination with neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
Presenter: Jun Wang
Session: E-Poster Display
Resources:
Abstract
1506P - The predictive value of 2-D myocardial strain for epirubicin-induced cardiotoxicity
Presenter: Ichrak Ben Abdallah
Session: E-Poster Display
Resources:
Abstract